 
|
Chantix Contact Practice Group  In November of 2007 the FDA initiated a safety review of Chantix after it received reports of 55 suicides and 199 suicidal thoughts possibly linked to Chantix use. The FDA said that its preliminary assessment revealed that many of the cases reflected new-onset of depressed mood, suicidal ideation, and changes in emotion and behavior within days to weeks of initiating Chantix treatment. The role of Chantix in these cases is not clear, the FDA said, because smoking cessation, with or without treatment, is associated with nicotine withdrawal symptoms and has also been associated with the exacerbation of underlying psychiatric illness. However, not all patients described in these cases had pre-existing psychiatric illness and not all had discontinued smoking. At that time, the FDA recommended that doctors monitor patients taking Chantix for behavior and mood changes. If you or someone close to you has been harmed by taking Chantix and you would like additional information please contact us. |
Chantix, manufactured by Pfizer, Inc., is a leading smoking cessation drug approved for use in 2006. Warnings have since been issued that it can cause a variety of adverse side effects including depression, severe mood swings and even suicide. Chantix has been linked to 63 deaths and thousands of reports of psychiatric symptoms in the United States and Great Britain in the past year. Despite the fact that the FDA recently issued a warning about serious Chantix side effects, the dangerous medication is still being aggressively marketed without warning of the potential risks it poses.